Frédéric Chéreau
Chief Executive Officer at LOGICBIO THERAPEUTICS, INC.
Profile
Frédéric Chéreau is currently the Chief Executive Officer at MYOSIX SA since 2009.
He is also the President, Chief Executive Officer & Director at LogicBio Therapeutics, Inc. since 2016.
Additionally, he serves as the Chairman at Maisons & Cités d'HLM.
Mr. Chéreau's current positions also include being the Chairman at Horama SA since 2022 and the Senior VP-Strategy & Business Development at Alexion Pharmaceuticals, Inc. since 2022.
He is a Member-Supervisory Board at Dynacure SA since 2017.
Mr. Chéreau has previously worked as the President & Chief Executive Officer at Pervasis Therapeutics, Inc. He was the Executive Chairman at Syndexa Pharmaceuticals Corp.
from 2011 to 2012.
Mr. Chéreau also served as the Director at French American Chamber of Commerce New England from 2008 to 2014.
He held the position of GM-Cardiovascular Business Unit & VP at Genzyme Corp.
from 1999 to 2008.
Mr. Chéreau was the President & Chief Operating Officer at aTyr Pharma, Inc. from 2014 to 2015.
He was the Chief Operating Officer at MG Biotherapeutics LLC.
Mr. Chéreau worked as the Senior Vice President at Shire Human Genetic Therapies, Inc. from 2012 to 2013 and as the Senior Vice President-Global Franchise Lead at Shire Pharmaceuticals, Inc. from 2012 to 2013.
Mr. Chéreau's education includes an MBA from INSEAD in 2004.
He completed his undergraduate studies at Université Paris 1 Panthéon-Sorbonne in 1990 and his graduate studies at Groupe de Sup de Co La Rochelle in 1993.
Frédéric Chéreau active positions
| Companies | Position | Start |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Chief Executive Officer | 2016-03-31 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2022-10-31 |
MYOSIX SA
 MYOSIX SA BiotechnologyHealth Technology MYOSIX SA develops cell-based therapeutics. The company is involved in the development of autologous cell therapy products for the treatment of cardiopathies and certain forms of myopathy in humans. MYOSIX specializes in the development of cell-based therapeutics against other pathologies like cancers. MYOSIX is also engaged in a number of R&D projects and develops a cell and tissue bank for therapeutic or R&D purposes. The company was founded by Vilquin, Marolleau, Scorsin, Eisenmann and Halioua in 2000 and is headquartered in Saint-Germain-en-Laye, France. | Chief Executive Officer | - |
Horama SA
 Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Chairman | 2022-10-19 |
Maisons & Cités d'HLM
 Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | Chairman | - |
Dynacure SA
 Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Director/Board Member | 2016-12-31 |
Former positions of Frédéric Chéreau
| Companies | Position | End |
|---|---|---|
| ATYR PHARMA, INC. | President | 2015-07-12 |
| French American Chamber of Commerce New England | Director/Board Member | 2013-12-31 |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 2013-11-30 |
| ░░░░░ ░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Training of Frédéric Chéreau
| INSEAD | Masters Business Admin |
| Université Paris 1 Panthéon-Sorbonne | Undergraduate Degree |
| Groupe de Sup de Co La Rochelle | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| Private companies | 13 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Pervasis Therapeutics, Inc.
 Pervasis Therapeutics, Inc. Medical SpecialtiesHealth Technology Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. The company was founded by Robert S. Langer Jr. and Helen Marie Nugent in 2004 and is headquartered in Waltham, MA. | Health Technology |
MYOSIX SA
MYOSIX SA BiotechnologyHealth Technology MYOSIX SA develops cell-based therapeutics. The company is involved in the development of autologous cell therapy products for the treatment of cardiopathies and certain forms of myopathy in humans. MYOSIX specializes in the development of cell-based therapeutics against other pathologies like cancers. MYOSIX is also engaged in a number of R&D projects and develops a cell and tissue bank for therapeutic or R&D purposes. The company was founded by Vilquin, Marolleau, Scorsin, Eisenmann and Halioua in 2000 and is headquartered in Saint-Germain-en-Laye, France. | Health Technology |
| MG Biotherapeutics LLC | |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Syndexa Pharmaceuticals Corp.
 Syndexa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Syndexa Pharmaceuticals Corp. developed novel medicines for the treatment and prevention of metabolic diseases. The company was founded in 2005 and was headquartered in Watertown, MA. | Health Technology |
Maisons & Cités d'HLM
Maisons & Cités d'HLM Real Estate DevelopmentFinance Maisons & Cités d'HLM provides real estate services. It offers builds social housing, as well as offers renting, selling, and buying of properties. The company was founded on December 31, 1985 and is headquartered in Douai, France. | Finance |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Health Technology |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Health Services |
| French American Chamber of Commerce New England |
- Stock Market
- Insiders
- Frédéric Chéreau
